key: cord-1031095-t6577sbh authors: von Stillfried, Saskia; Acker, Till; Aepfelbacher, Martin; Baretton, Gustavo; Bülow, Roman David; Bürrig, Karl-Friedrich; Holtherm, Hans-Ulrich; Jonigk, Danny; Knüchel, Ruth; Majeed, Raphael W.; Röhrig, Rainer; Wienströer, Jan; Boor, Peter title: Cooperative approach of pathology and neuropathology in the COVID-19 pandemic: German registry for COVID-19 autopsies (DeRegCOVID) and German network for autopsies in pandemics (DEFEAT PANDEMIcs) date: 2021-03-15 journal: Pathologe DOI: 10.1007/s00292-020-00897-3 sha: a33812c10aa464ae320fbf1d6a5d8c22d0199be3 doc_id: 1031095 cord_uid: t6577sbh BACKGROUND: Autopsy is an important tool for understanding the pathogenesis of diseases, including COVID-19. MATERIAL AND METHODS: On 15 April 2020, together with the German Society of Pathology and the Federal Association of German Pathologists, the German Registry of COVID-19 Autopsies (DeRegCOVID) was launched (www.DeRegCOVID.ukaachen.de). Building on this, the German Network for Autopsies in Pandemics (DEFEAT PANDEMIcs) was established on 1 September 2020. RESULTS: The main goal of DeRegCOVID is to collect and distribute de facto anonymized data on potentially all autopsies of people who have died from COVID-19 in Germany in order to meet the need for centralized, coordinated, and structured data collection and reporting during the pandemic. The success of the registry strongly depends on the willingness of the respective centers to report the data, which has developed very positively so far and requires special thanks to all participating centers. The rights to own data and biomaterials (stored decentrally) remain with each respective center. The DEFEAT PANDEMIcs network expands on this and aims to strengthen harmonization and standardization as well as nationwide implementation and cooperation in the field of pandemic autopsies. CONCLUSIONS: The extraordinary cooperation in the field of autopsies in Germany during the COVID-19 pandemic is impressively demonstrated by the establishment of DeRegCOVID, the merger of the registry of neuropathology (CNS-COVID19) with DeRegCOVID and the establishment of the autopsy network DEFEAT PANDEMIcs. It gives a strong signal for the necessity, readiness, and expertise to jointly help manage current and future pandemics by autopsy-derived knowledge. The WHO declared the global outbreak of COVID-19 a pandemic on 11 March 2020. On September 7, the WHO Director-General stated, "This will not be the last pandemic. History teaches us that outbreaks and pandemics are a fact of life. But when the next pandemic comes, the world must be ready-more ready than it was this time" [8] . To cope with the consequences of the disease (coronavirus disease 2019, and pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to prepare for future pandemics, it is of utmost importance to mobilize and harmonize basic and applied medical research both nationally and globally [15] , and to collect, analyze, and make the data available, if possible in a centralized manner. This is already happening in various registries, such as the LEOSS registry (Lean European Open Survey on SARS-CoV-2 infected patients) and the CAPACITYCOVID registry (registry of patients with COVID-19 including cardiovascular risks and complications). An autopsy is an essential tool for understanding disease pathogenesis, espe- cially infectious diseases caused by new or so-called emerging or re-emerging viruses, e.g. influenza viruses, Ebola virus, hantaviruses, and coronaviruses (CoV), e.g., SARS-CoV [11] , MERS-CoV or currently SARS-CoV-2 [19] . Already in the first published postmortem studies on COVID-19, the pathogenicity mechanisms underlying the particularly severe and fatal courses of the disease with potential therapeutic effects were identified. These organ-specific consequences of COVID-19 are discussed in detail in the corresponding articles in this special issue of the journal, especially for the lung and heart [2] , kidney [3] , or the central nervous system [14] . The recommendations for performing autopsies in Germany during the first wave of the SARS-CoV-2 pandemic ranged from the recommendation by the Robert Koch Institute to avoid autopsies due to occupational safety aspects, to a largely united position of German pathologists, forensic pathologists, and their professional societies for performing autopsies, for which there are many years of experience and guidelines based on other infectious diseases. The knowledge gained through autopsies made it clear to medical professionals, German health authorities, and the broader public that autopsies are an important and necessary tool for understanding the pathophysiology of COVID-19 and new or reemerging diseases in general. Autopsies can very quickly provide important information that can significantly improve the risk assessment, diagnosis, and treatment of patients. Various institutes of pathology have published recommendations or reports on the practical implementation of COVID-19 autopsies [4, 9, 10, 13, 16] , which are also discussed in another article in this special issue [5] . To better manage the current pandemic, characterize the disease, gain new insights, and create preparedness structures for future epidemics and pandemics, it is necessary to establish central structures, such as a national autopsy registry and general procedural recommendations for conducting infectious autopsies, data collection, and biobanking in the event of a pandemic. We have established the first national registry for COVID-19 autopsies (DeRegCOVID). Extending this, we also launched the German Research Network for Pandemic Autopsies (DEFEAT PANDEMIcs) as part of the Network of University Medicine (NUM) to implement a harmonized data collection and systematic and standardized analysis of the suitability of the collected postmortem tissues and body fluids for virological, genomic, transcriptomic and imaging analyses on a nationwide level (https://www. netzwerk-universitaetsmedizin.de/). Given the need for centralized and coordinated support, reporting, systematic biobanking, and structured data harmonization, we launched the first version of a Germany-wide registry of COVID-19 autopsies on April 15 (DeRegCOVID, . Fig. 1 ). Further information can be found on the website (www.DeRegCOVID.ukaachen.de) or inquired via e-mail (Covid.Pathologie@ ukaachen.de). The interdisciplinary team of DeRegCOVID currently consists of 13 employees from the Institute of Pathology (medical and scientific management), Institute of Medical Informatics (technical management), Clinical Trial Center Aachen (CTC-A, project management) as well as other employees from the Legal and Data Security Division of the University Hospital Aachen. The main objective of this centralized national registry for COVID-19 autopsies is to collect, categorize, analyze and provide harmonized and factually anonymous data on all autopsies and related biomaterials of COVID-19 deceased persons in Germany to the medical and scientific community (. Fig. 2 , from [18] ). The DeRegCOVID is located at the University Hospital RWTH Aachen and was developed with the close support of the Federal Association of German Pathologists e. V. (BDP) and the German Society of Pathology (DGP). It is financed by the Federal Ministry of Health and has been positively reviewed by the Robert Koch Institute. Data collection is based on WHO recommendations and the German S1 guideline for performing autopsies. Many academic and nonacademic centers, including centers of the German Federal Armed Forces, are already involved in the registry, thus incorporating and implementing ethical and legal frameworks for all German autopsy centers. Centers performing COVID-19 autopsies report epidemiological data (age, sex, time of death), data on preanalytical factors (time between death and autopsy), data on known clinical course, underlying diseases, findings and causes of death determined during the autopsy, and metadata on type and amount of locally archived tissue samples (e.g., organ/topography, FFPE, cryoasservation). Entry into the reporting system is done via the internet (https://covidpat. ukaachen.de/), using password-protected login data specifically set up for each center. The platform is constantly being optimized, especially following feedback from users, to further improve data entry. Experience has shown that, depending on the complexity of an autopsy case, it currently takes between 15 and 30 min to enter data. The staff of DeRegCOVID assists with all questions (Covid.Pathologie@ukaachen.de). The collected sample material remains with the respective centers (decentralized biobanking, . Fig. 2a) . The DeRegCOVID follows the principle that all centers retain the rights to their reported data and materials. For data reporting, each center must comply with local regulatory requirements, especially regarding ethical and data protection issues. DeRegCOVID in order to meet the need for centralized, coordinated, and structured data collection and reporting during the pandemic. The success of the registry strongly depends on the willingness of the respective centers to report the data, which has developed very positively so far and requires special thanks to all participating centers. The rights to own data and biomaterials (stored decentrally) remain with each respective center. The DEFEAT PANDEMIcs network expands on this and aims to strengthen harmonization and standardization as well as nationwide implementation and cooperation in the field of pandemic autopsies. Conclusions. The extraordinary cooperation in the field of autopsies in Germany during the COVID-19 pandemic is impressively demonstrated by the establishment of DeRegCOVID, the merger of the registry of neuropathology (CNS-COVID19) with DeRegCOVID and the establishment of the autopsy network DEFEAT PANDEMIcs. It gives a strong signal for the necessity, readiness, and expertise to jointly help manage current and future pandemics by autopsy-derived knowledge. Autopsy · Interoperability · Registries · SARS-CoV-2 · Tissue banks Autopsie · Interoperabilität · Register · SARS-CoV-2 · Gewebebanken actively supports the participating centers in meeting the local regulatory requirements. After curation and harmonization, the available data are centrally evaluated and reported to the medical and scientific community: to the Professional Association of Pathologists and Neuropathologists (Bundesverband An important aspect and a central task of DeRegCOVID is the implementation of interfaces to national and international data platforms. The reporting centers will provide their centrally curated data in a syntactically and semantically standardized and annotated form so that they can then be uploaded into national and international research projects. One such example is the research data platform of the National Pandemic Cohort Network (NAPKON) within the Network of University Medicine (NUM; https:// www.netzwerk-universitaetsmedizin. de/). Furthermore, interfaces to the structures of the registries/biobanks within the German Health Centers, e.g., German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL), are planned. For this purpose, data set definition and export interfaces will be continuously adapted to the evolving definition of the GECCO data set (German Corona Consensus data set). Cooperation with international initiatives is also planned. In addition to the core tasks of central data acquisition and reporting, DeRegCOVID fulfills several other tasks. These include, for example, support in questions concerning practical aspects of COVID-19 autopsies, as a central source of information for procedural instructions and recommendations, e.g., safety measures and occupational health and safety in the context of autopsies or biobanking of biomaterial of COVID-19 deceased persons. Another important task is to serve as a mediator between participating centers and national or international scientists. If scientists require an autopsy biomaterial or data for a study, they can send a request to DeRegCOVID (an application form is available at www. DeRegCOVID.ukaachen.de). The team of DeRegCOVID first checks the plausibility of the request, i.e., whether the project can be answered by the available biomaterial or data from the registry. Our initial experience shows that some requests cannot be served, given that the questions cannot be answered with the proposed methods on postmortem biomaterial and available data. In case of suitable inquiries, the centers with available biomaterials and data are identified and contract between the requesting researchers and the reporting centers and biobanks with appropriate material is established (a function of "scientific Tinder"). Thus, it is possible to identify cases in a specific disease stage (e.g., particularly early or late stage), with a specific pathological diseases pattern (e.g., hemophagocytic lymphohistiocytosis), with specific comorbidities (e.g., diabetes, kidney disease) or therapies (e.g., no therapy, long-term or intensive therapy, ECMO). This also facilitates multicenter studies that include a sufficiently large number of cases and to produce robust results. The first example, which was supported by DeRegCOVID, is the work describing the pathological and molecular characteristics of pulmonary involvement in COVID-19 based on autopsies, published in the New England Journal of Medicine [1] . Further studies have been published in the meantime [6, 7, 12] , and some are under review or in preparation. Compartment-specific detection of the virus in the tissues of COVID-19, but often also the basic confirmation of SARS-CoV-2 infection in deceased persons, are important aspects in the evaluation of autopsy results. Therefore another task of DeRegCOVID is to support the detection of SARS-CoV-2 in tissues for which different methods are available. Method-specific advantages and disadvantages and indications of the different methods are discussed in another article in this issue [17] . As a consequence of the work described above, which has shown the importance of autopsies for understanding COVID-19, the German Research Network for Autopsies in Pandemics was founded (DEFEAT PANDEMIcs). The DEFEAT PANDEMIcs network currently consists of 27 university centers (with more than 50 pathological, neuropathological, and forensic medicine institutions) and 14 non-university research institutions, including the Robert Koch Institute (. Fig. 3 ). It is funded by the German Federal Ministry of Education and Research within the framework of the Network of University Medicine (NUM; https://www.networkuniversitaetsmedizin.de/). The goal of the DEFEAT PANDEMIcs network is to implement and further improve a systematic, structured, harmonized, comprehensive, and rapid analysis of epidemiological data, findings, and tissue samples from autopsies during the COVID-19 pandemic and future pandemics or epidemics on a nationwide level. DeRegCOVID is the central and sustainable data platform, the information broker, and thus the electronic backbone of the DEFEAT PANDEMIcs network. Due to the modular and thus scalable architecture of the registry, DeRegCOVID can be supplemented by any number of centers. All functions of DeRegCOVID are also provided for the entire network. The Germanywide registry CNS-COVID19 (www. cns-covid19.de), founded by the German Society for Neuropathology and Neuroanatomy (DGNN), was merged with DeRegCOVID within the framework of DEFEAT PANDEMIcs. The registry CNS-COVID19, located at the Justus-Liebig University of Giessen, supported the systematic research of central and peripheral nervous system involvement in COVID-19 via standardized sampling and decentralized biobanking of human tissue samples from defined CNS/PNS/ muscle areas in COVID-19 autopsies and is supported by more than 35 university and non-university neuropathology and pathology institutions. The tasks of DEFEAT PANDEMIcs cover three subject areas (see also . Fig. 4 An early, unified public relations effort by German pathologists and pathological societies made it clear to medical professionals, German health authorities, and the public that autopsies remain an essential tool for understanding the pathophysiology of emerging diseases in general and of COVID-19 in particular. This was also demonstrated by the important and already early autopsy-based medical-scientific work, many of which originated from the German-speaking countries and which in part led to changes in therapeutic strategies for severe COVID-19 courses. The collaborative approach was further strengthened at a very early stage by the establishment of the centralized national registry for COVID-19 autopsies (DeRegCOVID) and is being further developed with the German Research Network for Pandemic Autopsies (DEFEAT PANDEMIcs). These sustainable structures will help us to jointly manage the current pandemic as well as future epi-and pandemics. Conclusion for practice 4 The German Registry for COVID-19 Autopsies (DeRegCOVID; www. DeRegCOVID.ukaachen.de): j Collects data centrally and electronically of ideally all COVID-19 autopsies in Germany. j Any institute or center can participate. j Supports all centers and researchers. j The data sovereignty and all biomaterials remain with the respective institutes or centers. j Analyzes and reports on collected data in cooperation with the participating centers. j Acts as the electronic backbone and sustainable structure for the DEFEAT PANDEMIcs network. 4 The German Network for Autopsies in Pandemics (DEFEAT PANDEMIcs): j Aims at a nationwide implementation of high-quality, standardized, and harmonized data collection and biobanking of autopsies in pandemics. j Is a network of 27 university hospitals with more than 60 participating institutes (pathology, neuropathology, and forensic medicine) and 14 associated societies and partners. j Serves as a preparedness structure for future pandemics. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 COVID-19: effects on the lungs and heart COVID-19 effects on the kidney COVID-19 autopsies Practical aspects of COVID-19 autopsies Postmortem conjunctival and nasopharyngeal swabs in SARS-CoV-2 infected and uninfected patients Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue diseaseassociated interstitial lung disease (CTD-ILD) int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-themedia-briefing-on-covid Autopsy in suspected COVID-19 cases Covid-19: postmortem diagnostic and biosafety considerations Lung pathology of fatal severe acute respiratory syndrome Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia Risk assessment of autopsy-acquired SARS-coV-2 Coronavirus (COVID-19) COVID-19 and the central and peripheral nervous system COVID-19, chronicle of an expected pandemic Autopsies of COVID-19 deceased? Methods of SARS-CoV-2 detection in tissue Autopsy registry can facilitate COVID-19 research Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China Acknowledgements. The authors would like to thank all centers and institutes that perform COVID-19 autopsies and participate in DeRegCOVID and DEFEAT PANDEMIcs. Our thanks also apply to the many involved coworkers of the University Clinic of the RWTH Aachen, who helped to develop, further optimize, and maintain DeRegCOVID. The authors would especially like to thank the Dean of the Medical Faculty of the RWTH Aachen University, Univ. For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.